API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Adavosertib (AZD1775, MK-1775), a clinical-stage inhibitor of tyrosine kinase WEE1, exhibited a broad anti-cancer activity across all hematological and solid tumor types with IC50 values ranging from 0.06 to 10 µM, matching consistently high expression of WEE1 gene.
Lead Product(s): Adavosertib
Therapeutic Area: Oncology Product Name: AZD1775
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Reaction Biology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022